Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL

Resistance to standard immunochemotherapy remains an unmet challenge in diffuse large B-cell lymphoma (DLBCL), and aberrant DNA methylation may contribute to chemoresistance. Promising early-phase results were reported with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Peter, Bartlett, Nancy L., Chavez, Julio C., Reagan, John L., Smith, Sonali M., LaCasce, Ann S., Jones, Jeffrey, Drew, James, Wu, Chengqing, Mulvey, Erin, Revuelta, Maria V., Cerchietti, Leandro, Leonard, John P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9211445/
https://www.ncbi.nlm.nih.gov/pubmed/34428285
http://dx.doi.org/10.1182/blood.2021011679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9211445/
https://www.ncbi.nlm.nih.gov/pubmed/34428285
http://dx.doi.org/10.1182/blood.2021011679

Ejemplares similares